Drug Profile
Actoxumab/bezlotoxumab - Merck & Co
Alternative Names: 3D8; Bezlotoxumab/actoxumab; CDA-1/CDA-2; GS-CDA-1/MDX-1388; MBL-CDA1/MBL-CDB1; MDX-066 + MDX-1388; MDX-066/MDX-1388; MK-3415 + MK-6072; MK-3415/MK-6072; MK-3415ALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Medarex; University of Massachusetts Medical School
- Developer Bristol-Myers Squibb; Merck & Co; University of Massachusetts Medical School
- Class Antidiarrhoeals; Monoclonal antibodies
- Mechanism of Action Clostridium difficile tcdA protein inhibitors; Clostridium difficile toxB protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 24 Jan 2018 No recent reports on development identified - Phase-III for Clostridium difficile infections in Japan, Finland, Sweden, Poland, Greece, Belgium, Italy, Czech Republic, United Kingdom, Austria, Spain, Portugal, Denmark, Germany and USA (IV)
- 20 Sep 2015 Merck announces intention to submit regulatory applications in USA, European Union and Canada in 2015
- 20 Sep 2015 Efficacy and adverse events data from the phase III MODIFY I and II trials in Clostridium difficile infections released by Merck